Lacosamide Accord

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

lacosamide

Available from:

Accord Healthcare S.L.U.

ATC code:

N03AX18

INN (International Name):

lacosamide

Therapeutic group:

Antiepileptics,

Therapeutic area:

Epilepsy

Therapeutic indications:

Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.Lacosamide Accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.•         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Product summary:

Revision: 12

Authorization status:

Authorised

Authorization date:

2017-09-18

Patient Information leaflet

                                88
B. PACKAGE LEAFLET
89
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LACOSAMIDE ACCORD 50 MG FILM-COATED TABLETS
LACOSAMIDE ACCORD 100 MG FILM-COATED TABLETS
LACOSAMIDE ACCORD 150 MG FILM-COATED TABLETS
LACOSAMIDE ACCORD 200 MG FILM-COATED TABLETS
lacosamide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lacosamide Accord is and what it is used for
2.
What you need to know before you take Lacosamide Accord
3.
How to take Lacosamide Accord
4.
Possible side effects
5.
How to store Lacosamide Accord
6.
Contents of the pack and other information
1.
WHAT LACOSAMIDE ACCORD IS AND WHAT IT IS USED FOR
WHAT LACOSAMIDE ACCORD IS
Lacosamide Accord contains lacosamide. This belongs to a group of
medicines called “antiepileptic
medicines”. These medicines are used to treat epilepsy.

You have been given this medicine to lower the number of fits
(seizures) you have.
WHAT LACOSAMIDE ACCORD IS USED FOR

Lacosamide Accord is used:
o
on its own and in association with other antiepileptic medicines in
adults, adolescents and
children aged 2 years and older to treat a certain type of epilepsy
characterised by the
occurrence of partial-onset seizure with or without secondary
generalisation. In this type of
epilepsy, fits first affect only one side of your brain. However,
these may then spread to
larger areas on both sides of your brain.
o
in association with other antiepileptic medicines in adults,
adolescents and children aged 4
years and older to treat primary generalised tonic- clonic seizures
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lacosamide Accord 50 mg film-coated tablets
Lacosamide Accord 100 mg film-coated tablets
Lacosamide Accord 150 mg film-coated tablets
Lacosamide Accord 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Lacosamide Accord 50 mg film-coated tablets
One film-coated tablet contains 50 mg lacosamide.
Lacosamide Accord 100 mg film-coated tablets
One film-coated tablet contains 100 mg lacosamide.
Lacosamide Accord 150 mg film-coated tablets
One film-coated tablet contains 150 mg lacosamide.
Lacosamide Accord 200 mg film-coated tablets
One film-coated tablet contains 200 mg lacosamide.
Excipient(s) with known effect:
50 mg: Each film-coated tablet contains 0.105 mg of lecithin (soya)
100 mg: Each film-coated tablet contains 0.210 mg of lecithin (soya)
150 mg: Each film-coated tablet contains 0.315 mg of lecithin (soya)
200 mg: Each film-coated tablet contains 0.420 mg of lecithin (soya)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Lacosamide Accord 50 mg film-coated tablets
Pink, oval, approximately 10.3 x 4.8 mm, coated tablets, debossed
“L” on one side and “50” on other
side.
Lacosamide Accord 100 mg film-coated tablets
Dark yellow, oval, approximately 13.0 x 6.0 mm, coated tablets,
debossed “L” on one side and “100” on
other side.
Lacosamide Accord 150 mg film-coated tablets
Salmon, oval, approximately 15.0 x 6.9 mm, coated tablets, debossed
“L” on one side and “150” on
other side.
Lacosamide Accord 200 mg film-coated tablets
3
Blue, oval, approximately 16.4 x 7.6 mm, coated tablets, debossed
“L” on one side and “200” on other
side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Lacosamide Accord is indicated as monotherapy in the treatment of
partial-onset seizures with or
without secondary generalisation in adults, adolescents and children
from 2 years of age with epilepsy.
Lacosamide Accord is indicated as adjunctive therapy

in th
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-08-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-08-2023
Public Assessment Report Public Assessment Report Bulgarian 27-09-2017
Patient Information leaflet Patient Information leaflet Spanish 16-08-2023
Public Assessment Report Public Assessment Report Spanish 27-09-2017
Patient Information leaflet Patient Information leaflet Czech 16-08-2023
Public Assessment Report Public Assessment Report Czech 27-09-2017
Patient Information leaflet Patient Information leaflet Danish 16-08-2023
Public Assessment Report Public Assessment Report Danish 27-09-2017
Patient Information leaflet Patient Information leaflet German 16-08-2023
Public Assessment Report Public Assessment Report German 27-09-2017
Patient Information leaflet Patient Information leaflet Estonian 16-08-2023
Public Assessment Report Public Assessment Report Estonian 27-09-2017
Patient Information leaflet Patient Information leaflet Greek 16-08-2023
Public Assessment Report Public Assessment Report Greek 27-09-2017
Patient Information leaflet Patient Information leaflet French 16-08-2023
Public Assessment Report Public Assessment Report French 27-09-2017
Patient Information leaflet Patient Information leaflet Italian 16-08-2023
Public Assessment Report Public Assessment Report Italian 27-09-2017
Patient Information leaflet Patient Information leaflet Latvian 16-08-2023
Public Assessment Report Public Assessment Report Latvian 27-09-2017
Patient Information leaflet Patient Information leaflet Lithuanian 16-08-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-08-2023
Public Assessment Report Public Assessment Report Lithuanian 27-09-2017
Patient Information leaflet Patient Information leaflet Hungarian 16-08-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 16-08-2023
Public Assessment Report Public Assessment Report Hungarian 27-09-2017
Patient Information leaflet Patient Information leaflet Maltese 16-08-2023
Public Assessment Report Public Assessment Report Maltese 27-09-2017
Patient Information leaflet Patient Information leaflet Dutch 16-08-2023
Public Assessment Report Public Assessment Report Dutch 27-09-2017
Patient Information leaflet Patient Information leaflet Polish 16-08-2023
Public Assessment Report Public Assessment Report Polish 27-09-2017
Patient Information leaflet Patient Information leaflet Portuguese 16-08-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 16-08-2023
Public Assessment Report Public Assessment Report Portuguese 27-09-2017
Patient Information leaflet Patient Information leaflet Romanian 16-08-2023
Public Assessment Report Public Assessment Report Romanian 27-09-2017
Patient Information leaflet Patient Information leaflet Slovak 16-08-2023
Public Assessment Report Public Assessment Report Slovak 27-09-2017
Patient Information leaflet Patient Information leaflet Slovenian 16-08-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 16-08-2023
Public Assessment Report Public Assessment Report Slovenian 27-09-2017
Patient Information leaflet Patient Information leaflet Finnish 16-08-2023
Public Assessment Report Public Assessment Report Finnish 27-09-2017
Patient Information leaflet Patient Information leaflet Swedish 16-08-2023
Public Assessment Report Public Assessment Report Swedish 27-09-2017
Patient Information leaflet Patient Information leaflet Norwegian 16-08-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 16-08-2023
Patient Information leaflet Patient Information leaflet Icelandic 16-08-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 16-08-2023
Patient Information leaflet Patient Information leaflet Croatian 16-08-2023
Public Assessment Report Public Assessment Report Croatian 27-09-2017

Search alerts related to this product